Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on immunotherapy for melanoma.

Antoni Ribas1

  • 1Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles School of Medicine, 90095, USA. ARibas@mednet.ucla.edu

Journal of the National Comprehensive Cancer Network : JNCCN
|August 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.

Nature communications·2026
Same author

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

Cancer discovery·2026
Same author

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.

Nature communications·2026
Same author

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.

Targeted oncology·2026

Modern immunotherapies, including cytokines and cell-based vaccines, show promise for treating metastatic melanoma. Understanding immune activation is key to improving treatment responses and overcoming resistance.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Metastatic melanoma treatment has historically relied on high-dose interleukin-2 (IL-2), offering prolonged responses in some patients.
  • Numerous experimental immunotherapy strategies are under investigation to enhance anti-tumor immune responses.

Purpose of the Study:

  • To review current and emerging experimental immunotherapy approaches for metastatic melanoma.
  • To highlight the role of a deeper understanding of immune system regulation in developing novel therapies.

Main Methods:

  • Review of various immunotherapy modalities including cytokines, vaccines, cell therapies, and targeted antibodies.
  • Discussion of approaches aimed at inducing cytotoxic T-cell responses against tumors.

Related Experiment Videos

Main Results:

  • Experimental immunotherapies encompass a wide range of strategies, from cytokines (IL-7, IL-21) and immunocytokines to cell-based vaccines and adoptive T-cell transfer.
  • Novel targets include Toll-like receptor ligands and antibodies against CTLA4, CD40, and CD137.
  • These advanced methods leverage improved knowledge of immune activation and regulation.

Conclusions:

  • Enhanced understanding of immune mechanisms is driving the development of more effective immunotherapies for melanoma.
  • Higher response rates observed with modern approaches facilitate the study of tumor sensitivity and resistance to immunotherapy.